AAN: Early Research Promising for Immunotherapy in MS

Share this content:
AAN: Early Research Promising for Immunotherapy in MS
AAN: Early Research Promising for Immunotherapy in MS

FRIDAY, April 21, 2017 (HealthDay News) -- An experimental immune-system therapy appears safe for patients with progressive forms of multiple sclerosis, and may ease symptoms in some, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 22 to 28 in Boston.

Michael Pender, M.D., Ph.D., of the University of Queensland in Brisbane, Australia, and colleagues conducted a phase 1 trial investigating use of adoptive immunotherapy in six patients with progressive MS with moderate-to-severe disability. The team took samples of the patients' T cells, then altered the cells to boost their ability to recognize and attack the Epstein-Barr virus. Those T cells were infused back into the patients' blood, at gradually escalating doses over six weeks.

Over six months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, three showed symptom improvements within two to eight weeks of their first T-cell infusion.

"The best responses were seen in the two people who received T cells with the highest amount of reactivity to the Epstein-Barr virus," Pender said in a news release from the American Academy of Neurology. "The results add to the mounting evidence for a role of the Epstein-Barr virus infection in MS and set the stage for further clinical trials."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease


Sign up for myCME e-newsletters


More in Home

Older Adults Less Likely to Have Provider-Ordered Flu Testing

Older Adults Less Likely to Have Provider-Ordered Flu ...

Presence of influenza-like illness, younger age independently predict provider-ordered testing

Nutrients in Child's First 1,000 Days Key for Neurodevelopment

Nutrients in Child's First 1,000 Days Key for ...

Nutrition in prenatal period and first two years of life affects prenatal nutrient delivery, child development

In-Office Angiolytic Laser Effective for Vocal Polyps

In-Office Angiolytic Laser Effective for Vocal Polyps

Fewer adverse events for patients treated with laser plus concurrent polypectomy than laser alone

is free, fast, and customized just for you!

Already a member?

Sign In Now »